TieMed LLC

Easier to take formulations of high volume Rx products for patients who won't swallow pills - better clinical and pharmacoeconomic outcomes.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Princeton, NJ, USA
  • Currency USD
  • Founded May 2012
  • Employees 2
  • Website tiemed.com

Company Summary

Billions of pills are prescribed each year for chronic diseases but 40% of patients report difficulty swallowing pills. TieMed has secured the exclusive rights to commercialize in the US a unique formulation and manufacturing process to produce superior quality effervescent tablets that completely dissolve in 4oz of water. The lead compound for development is metformin, the standard first-line therapy for patients diagnosed with Type 2 diabetes.

Team

  • Graham G Lumsden
    CEO

    • 26-year veteran of the pharmaceutical industry; diverse leadership and management experience in both human and animal health (Merck & Co., Inc.)
    • Extensive experience in drug development, clinical trial design, regulatory strategy and commercialization, including several successful new product launches
    • QED Business Adviser at the University City Science Center in Philadelphia

  • Jim Self
    CBO

    • Founder, President at ProBiopharm, a global business development consultancy
    • Broad experience in pharmaceutical manufacturing, and global pharmaceutical and vaccine business development gained during 21 years at Merck & Co., Inc.
    • General Manager at Mission Pharmacal, responsible for the successful launch and commercialization of Binosto (alendronate) effervescent tablets for oral solution

  • Graham Lumsden

Advisors

  • Fahd Riaz, Morgan Lewis
    Lawyer
    Unconfirmed
    tbc
    Accountant
    Unconfirmed

Previous Investors

  • Local High Net Worth Individuals
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free